Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight

Exclusion Criteria

• •Febrile illness within 1 week before the start of the study
• •Hypersensitivity to riociguat and / or to inactive constituents
• •Smoking
• •Hemoglobin \<8 g/dL
• •Severe cerebrovascular or cardiac disorders, eg myocardial infarction less than 6 months prior to dosing, congestive heart failure of NYHA grade III or IV, severe arrhythmia requiring antiarrhythmic treatment
• •Evidence of hepatic encephalopathy related to chronic liver disease \> Grade II
• •Renal failure with a creatinine clearance \<40 mL/min
• •Resting heart rate in the awake subject below 45 BPM or above 100 BPM
• •Systolic blood pressure (SBP) below 100 mmHg or above 160 mmHg, Diastolic blood pressure (DBP) above 95 mmHg
• •Platelet count \<30 x 10\^9/L
• •History of bleeding within the past 3 months
• •AP \>4 times the upper limit of normal (ULN)
• •AST or ALT in conjunction with GGT \>= 4 times the ULN (an isolated elevation of GGT \>4 times ULN did not exclude the subject)
• •Serum albumin \<20 g/L
• •Diabetes mellitus with a fasting blood glucose \>220 mg/dL or HbA1c \>10%
• •Prothrombin time (Quick test) \<30%
• •Subjects who had undergone porto-caval shunt surgery
• •Use of medications known to interfere with hepatic metabolism (eg cimetidine, barbiturates, phenothiazines, etc) or known to alter other major organs or systems within 30 days prior to dosing
• •Severe infection, malignancy, psychosis, or any clinically significant illness within 4 weeks prior to dosing
• •Concomitant use of any medication except medications necessary for the treatment of the kidney disease or related complications
• •Concomitant use of phosphodiesterase-5 inhibitors, endothelin receptor antagonists (ERAs, eg bosentan), intravenous or inhalative prostacyclins, or nitrates
• •Concomitant use of potent CYP3A4 and P-gp inhibitors
• •Conspicuous findings in medical history or pre-study examination
• •History of relevant diseases of vital organs, central nervous system, or other organs
• •Resting heart rate in the awake subject below 45 BPM or above 90 BPM
• •SBP below 100 mmHg or above 145 mmHg, DBP above 95 mmHg
• •Regular daily consumption of more than 1 liter of usual beer or the equivalent quantity of approximately 40 g of alcohol in another form